T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, […]

The present invention relates to a method of treating HER2/EU overexpressing cancers. The inventors discovered that the heme-mediated formation of […]

Activating mutations in CTNNB1 gene encoding β-catenin is encountered in approximately 30% of hepatocellular carcinoma (HCC) and in more than 80% of […]

Dendritic cells (DCs) control the activation and infiltration of CD8+ T cells within the tumor microenvironment (TME). This process supports the […]

PI3K signalling is the most increased pathway in human cancers. The four isoforms of PI3K are thought to be activated by different redundant […]

The present invention provides methods and pharmaceutical compositions designed to intervene in this defective process and to promote or restore […]

Extranodal natural killer/T-cell lymphoma (ENKTCL) is an aggressive haematological malignancy. The treatment of ENKTCL is dependent on the extent of […]

EVs are being recognized as vectors for drug delivery. In particular, EV loading with targeting and therapeutic agents brings along an interesting […]

The inventors have developed a new system of optogenetics-based recombinant system allowing to target tumor cells to control in space and time tumor […]

The present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment […]